Compared with RT-PCR testing, Abbott's BinaxNow test had a sensitivity of 64 percent for samples from symptomatic people and nearly 36 percent for asymptomatic people.
The company, which is developing instrument-free, low-cost molecular diagnostics platform for infectious disease testing, plans to float its shares on the Nasdaq.
The firm said that it anticipates an increase in demand for its dried blood spot sampling product for antibody testing to confirm COVID-19 vaccine efficacy.
